Considerations when prescribing opioid agonist therapies for people living with HIV
Tarfa A, Lier A, Shenoi S, Springer S. Considerations when prescribing opioid agonist therapies for people living with HIV. Expert Review Of Clinical Pharmacology 2024, 17: 549-564. PMID: 38946101, PMCID: PMC11299801, DOI: 10.1080/17512433.2024.2375448.Peer-Reviewed Original ResearchMeSH KeywordsAnalgesics, OpioidAnti-HIV AgentsBuprenorphineDelayed-Action PreparationsDelivery of Health CareDrug InteractionsHealth Services AccessibilityHIV InfectionsHumansMethadoneNaltrexoneNarcotic AntagonistsOpiate Substitution TreatmentOpioid-Related DisordersPre-Exposure ProphylaxisUnited StatesConceptsOpioid agonist therapyOpioid use disorderAntiretroviral therapyAgonist therapyDiagnosed OUDOpioid use disorder managementUse disorderTreatment of opioid use disorderExtended-release naltrexonePotential drug interactionsOpioid use disorder treatmentPrescribed opioid agonist therapyLong-acting formulationPre-exposure prophylaxisOUD outcomesImprove HIV preventionIntersection of HIVOpioid antagonistHIV outcomesHIV epidemicOpioidHIVOpioid use disorder servicesPWHHIV preventionPerspectives on benefits and risks of creation of an “injection drug use” billing code
Sundaram G, Sato T, Goodman-Meza D, Haddad M, Thakarar K, Feinberg J, Springer S, Barton K, Butler N, Eaton E, Wurcel A. Perspectives on benefits and risks of creation of an “injection drug use” billing code. Journal Of Substance Use And Addiction Treatment 2024, 164: 209392. PMID: 38735482, DOI: 10.1016/j.josat.2024.209392.Peer-Reviewed Original ResearchInjection drug useSubstance use disordersInternational Classification of DiseasesIncreased riskICD-10 codesDrug useClassification of DiseasesHealthcare utilizationHealth servicesIncreased risk of overdoseFinancial reimbursementInternational ClassificationHealthcare systemRisk of overdoseTreatment servicesICD codesIdentifying peopleWell-beingPWIDUse disorderSystem of resource allocationHealthRiskImproved systemPotential benefits